News | Robotic Systems | May 13, 2016

New Study Reveals Safety and Feasibility of Robotically Assisted Percutaneous Coronary Intervention in Complex Cases

corpath, corindus, cath lab robot, CORA-PCI

May 13, 2016 — A first-of-its kind study using robotic technology to remotely control coronary guidewires and stents reported on the feasibility of performing percutaneous coronary intervention (PCI) on patients with complex coronary lesions. Similar clinical outcomes compared to the PCI procedure performed manually were reported. Results of the 18-month complex robotically assisted percutaneous coronary intervention (CORA-PCI) trial were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2016 Scientific Sessions. 

The technology of performing robotically assisted PCI is relatively new and was recently approved by the FDA. Previous studies were performed largely on patients with simple coronary lesions. “For the first time, we’ve shown nearly identical outcomes with a group of very complex patients,” said Ehtisham Mahmud, M.D., FACC, FSCAI, the study’s lead author and division chief, cardiovascular medicine and director, interventional cardiology and cardiac cath lab at the University of California, San Diego School of Medicine. He noted that approximately 80 percent of lesions treated in the CORA-PCI trial were complex, which is more reflective of contemporary interventional cardiology practice.

Consecutive robotic and manual procedures were performed by a single operator and a total of 334 PCI procedures were analyzed (108 robotic, 157 lesions; 226 manual, 336 lesions) in 315 patients (age 67.7 ± 11.8). The majority of patients (78 percent) were male. Clinical success was similar between the groups (99.1 percent for robotic PCI vs. 99.6 percent for manual PCI, p=0.64).

In the robotically assisted PCI group, over 90 percent of the procedures were performed entirely robotically or with minimal manual assistance. Procedure time was longer (robotic PCI 44:30 ± 26:04 min vs. manual PCI 36:34 ± 23:03 min, p=0.005) and remained significant after accounting for Syntax score, primary lesion length, and complexity (p=0.026); however, the longer procedure time was limited to the low complexity lesions. Propensity matched analysis (n=94 each group) confirmed the longer procedure time in the R-PCI group with comparable clinical success (98.9 percent vs. 100 percent, p=1). No increase in resource utilization or patient radiation exposure was reported with robotic PCI.

Furthermore, Mahmud said the data presented show that using robotic technology to perform PCI is a viable alternative to manual PCI with the potential benefits of reducing radiation exposure and orthopedic injuries to the interventional cardiologist.

Mahmud reports the following disclosures: Corindus, consulting and clinical trial support. No support received for this study.

For more information: www. SCAI.org/SCAI2016 

Related Content

Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Mobility May Predict Elderly Heart Attack Survivors' Repeat Hospital Stays
News | Cath Lab | April 23, 2019
Determining which elderly heart attack patients take longer to stand from a seated position and walk across a room may...
FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Providing Follow-Up Care After Heart Attack Helps Reduce Readmissions, Deaths
News | Cath Lab | April 09, 2019
A program designed to help heart attack patients with the transition from hospital to outpatient care can reduce...
TherOx Receives FDA Approval for SuperSaturated Oxygen Therapy
Technology | Cath Lab | April 08, 2019
TherOx Inc. announced that the U.S. Food and Drug Administration (FDA) granted premarket approval for its...
Cook Medical Recalls Transseptal Needle Due to Risk of Detached Plastic Fragments
News | Cath Lab | March 20, 2019
March 20, 2019 — Cook Medical is recalling one lot of its...
Overlay Init